GIGAGEN INC - NEXT GEN RECOMBINANT POLYCLONAL ANTIBODY DISCOVERY PLATFORM FOR THE DEVELPMENT OF MEDICAL COUNTERMEASURES

PIID: 75A50124C00049Solicitation ID: BAA-23-100-SOL-00004

Signed Date: Dec 4, 2025Effective Date: Sep 25, 2024End Date: Closes in 547 days

Award $

$19.6M

Vendor

GIGAGEN INC

NAICS

541715

Signed Date

Dec 4, 2025

Key Details

Dollars Obligated

$19.6M

Base & All Options

Awarding Agency

Awarding Sub-Agency

Office of Assistant Secretary for Preparedness and Response

NAICS Code

Product Service Code

Q701 - SPECIALIZED MEDICAL SUPPORT

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Place of Performance

SAN CARLOS, CA, 940702727, CD-CA-15

NEXT GEN RECOMBINANT POLYCLONAL ANTIBODY DISCOVERY PLATFORM FOR THE DEVELPMENT OF MEDICAL COUNTERMEASURES

On Dec 4, 2025, Department of Health and Human Services obligated $19,633,226.89 to GIGAGEN INC for next gen recombinant polyclonal antibody discovery platform for the develpment of medical countermeasures. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in SAN CARLOS, CA. The contract is scheduled through Jan 6, 2028 — approximately 18 months remaining.